Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of RYVU THERAPEUTICSCS ZY-,40
No Price
Closing Price XWAR 30.04.2026:
24,00 PLN
30.04.2026 17:31
Current Prices from RYVU THERAPEUTICSCS ZY-,40
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
Düsseldorf
RTSAIA13.DUSB
EUR
30.04.2026 17:31
5,35 EUR
-
WSE
RVU.WA
PLN
30.04.2026 15:00
24,00 PLN
-
Quotrix
RTSAIA13.DUSD
EUR
30.04.2026 05:27
5,48 EUR
-
Share Float & Liquidity
Free Float77,60 %
Shares Float17,94 M
Shares Outstanding23,12 M
Company Profile for RYVU THERAPEUTICSCS ZY-,40 Share
Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, cancer metabolism, synthetic lethality, and immuno-oncology. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.
